Postantibiotic effect of ceftobiprole against 12 gram-positive organisms

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 11, 2006, Pages 3956-3958

  Pankuch, G A ^a   Appelbaum, P C ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTOBIPROLE;

ANTIMICROBIAL ACTIVITY; ARTICLE; DOSE RESPONSE; ENTEROCOCCUS; GRAM POSITIVE BACTERIUM; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; POSTANTIBIOTIC EFFECT; PRIORITY JOURNAL; STAPHYLOCOCCUS; STREPTOCOCCUS PNEUMONIAE;

ANTI-BACTERIAL AGENTS; BETA-LACTAMS; CEPHALOSPORINS; ENTEROCOCCUS FAECALIS; GRAM-POSITIVE BACTERIA; HUMANS; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

EID: 33750603827     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00724-06     Document Type: Article

References (13)

1. Bogdanovich, T., L. M. Ednie, S. Shapiro, and P. C. Appelbaum. 2005. Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin. Antimicrob. Agents Chemother. 49:4210-4219.
2. Cars, O., and I. Odenholt-Tornqvist. 1993. The postantibiotic subMIC effect in vitro and in vivo. J. Antimicrob. Chemother. 31:159-166.
3. Craig, W. 1993. Pharmacodynamics of antimicrobial agents as a basis for determining dosage regimens. Eur. J. Clin. Microbiol. Infect. Dis. 12(Suppl. 1):6-8.
4. Craig, W. A., and S. Gudmundsson. 1996. Postantibiotic effect, p. 296-329. In V. Lorian (ed.), Antibiotics in laboratory medicine. The Williams and Wilkins Co., Baltimore, Md.
5. Hebeisen, P., I. Heinze-Krauss, P. Angehrn, P. Hohl, M. G. Page, and R. L. Then. 2001. In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci. Antimicrob. Agents Chemother. 45:825-836.
6. Kosowska, K., D. B. Hoellman, G. Lin, C. Clark, K. Credito, P. McGhee, B. Dewasse, B. Bozdogan, S. Shapiro, and P. C. Appelbaum. 2005. Antipneumococcal activity of ceftobiprole, a novel broad-spectrum cephalosporin. Antimicrob. Agents Chemother. 49:1932-1942.
7. MacKenzie, F. M., and I. M. Gould. 1993. The post-antibiotic effect. J. Antimicrob. Chemother. 32:519-537.
8. Mouton, J. W., and N. Punt. 2001. Use of the t > MIC to choose between different dosing regimens of beta-lactam antibiotics. J. Antimicrob. Chemother. 47:500-501.
9. Murray, P. R., E. J. Baron, M. A. Pfaller, F. C. Tenover, and R. H. Yolken (ed.). 1995. Manual of clinical microbiology, 7th ed. American Society for Microbiology, Washington, D.C.
10. National Committee for Clinical Laboratory Standards. 2003. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 5th ed. Approved standard. NCCLS publication no. M7-A6. National Committee for Clinical Laboratory Standards, Villanova, Pa.
11. Odenholt-Tornqvist, I. 1993. Studies on the postantibiotic effect and the postantibiotic sub-MIC effect of meropenem. J. Antimicrob. Chemother. 31:881-892.
12. Odenholt-Tornqvist, I., E. Löwdin, and O. Cars. 1992. Postantibiotic subMIC effects of vancomycin, roxithromycin, sparfloxacin, and amikacin. Antimicrob. Agents Chemother. 36:1852-1858.
13. Schmitt-Hofmann, A., B. Roos, M. Schleimer, J. Sauer, A. Man, N. Nashed, T. Brown, A. Perez, E. Weidekamm, and P. Kovacs. 2004. Single-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers. Antimicrob. Agents Chemother. 48:2570-2575.